Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/45758
Registro completo de metadados
Campo DCValorIdioma
dc.creatorJoshi, Shashank-
dc.creatorParkar, Jalil-
dc.creatorAnsari, Abdul-
dc.creatorVora, Agam-
dc.creatorTalwar, Deepak-
dc.creatorTiwaskar, Mangesh-
dc.creatorPatil, Saiprasad-
dc.creatorBarkate, Hanmant-
dc.date.accessioned2020-12-04T17:38:26Z-
dc.date.available2020-12-04T17:38:26Z-
dc.date.issued2021-01-
dc.identifier.citationJOSHI, S. et al. Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases, [S.l.], v. 102, p. 501-508, Jan. 2021.pt_BR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1201971220322736pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/45758-
dc.description.abstractThe coronavirus disease-2019 (COVID-19) outbreak all over the world has led the researchers to strive to develop drugs or vaccines to prevent or halt the progression of this ailment. To hasten the treatment process, repurposed drugs are being evaluated. Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2. It has a wide therapeutic safety margin indicated by a wide CC50/EC50 ratio for a high dose. From the clinical studies in COVID-19, it has shown rapid viral clearance as compared to lopinavir/ritonavir (LPV/RTV) and superior recovery rate than umifenovir. Overall, favipiravir has shown promising results in clinical studies in China, Russia, and Japan, and more trials are underway in multiple countries, including USA, UK, and India. Recently, treatment guidelines from many countries and some states from India have included favipiravir in the treatment protocol. This review provides insights into the evidence-based evolving role of favipiravir in the management of COVID-19 infection with emphasis on benefits of initiating an early antiviral therapy with special focus on favipiravir, its pharmacodynamic, pharmacokinetic, in vitro, clinical data, and inclusion in the treatment protocols of COVID-19.pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceInternational Journal of Infectious Diseasespt_BR
dc.subjectAnti-viralpt_BR
dc.subjectClinical guidelinespt_BR
dc.subjectViral clearancept_BR
dc.subjectPharmacokineticpt_BR
dc.titleRole of favipiravir in the treatment of COVID-19pt_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.